Innovative Medicines Initiative ‘s AETIONOMY

Aetionomy, a public-private consortium funded by the Innovative Medicines Initiative (IMI), announced January, 2014 the launch of a 10,4 million Euro project focussing on organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy. Academic institutes, biotechnology companies and the pharmaceutical industry have joined forces to develope of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and applicate of this pipeline to derive clinically significant mechanistic taxonomies of neurodegenerative diseases. These taxonomies will represent multi-scale structural and functional understanding of the causal mechanisms of and possible treatments in PD and AD.

Related links: